
Youdao revenue slides 12.3% to RMB1.4 billion in Q3
Key points
- Youdao (NYSE:DAO) reported third-quarter 2026 revenue of RMB1.4 billion (US$213.1 million), down 12.3% year over year.
- GAAP net income increased to RMB33.4 million from RMB0.1 million, while operating income rose 19.2% to RMB33.7 million.
- Gross margin improved to 43.6% from 42.2%, supported by higher margins in online marketing and learning services.
Youdao (NYSE:DAO) reported third-quarter 2026 net revenue of RMB1.4 billion (US$213.1 million), down 12.3% year over year, while net income attributable to ordinary shareholders reached RMB33.4 million.
Online marketing revenue fell 8.8% to RMB674.3 million, learning services revenue declined 5.2% to RMB609.4 million, and smart-device revenue dropped 40.9% to RMB145.2 million, while gross margin improved to 43.6% from 42.2% despite gross profit falling 9.5% to RMB622.7 million.
Operating income increased 19.2% to RMB33.7 million, GAAP net income rose from RMB0.1 million to RMB33.4 million, and non-GAAP net income climbed to RMB45.9 million from RMB9.2 million, while total operating expenses declined to RMB589.0 million from RMB659.6 million.
Cash, cash equivalents, restricted cash, time deposits and short-term investments totalled RMB599.8 million at September 30, down from RMB743.2 million at December 31, 2025, while operating activities used RMB89 million in cash during the quarter.
Youdao operates learning services, online marketing and smart-device businesses, and said it would continue its AI-Native Strategy using its Confucius language models, while its share repurchase programme had bought approximately 7.5 million ADSs for US$33.8 million by September 30, 2026.
Frequently asked questions
More from United States
NetEase revenue falls 1.8% to RMB27.9 billion
Futu quarterly revenue increases 4.5% to HK$6.69 billion
Sunlands revenue falls 36.6% to RMB331.6 million
ATRenew revenue jumps 25.3% to RMB6.45 billion
Oil prices steady as supply surplus outlook offsets Middle East tensions
HUTCHMED reports positive preclinical results for HMPL-A830 cancer candidate


